Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373201 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
NCT03373201 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 320 participants.
The verdict
NCT03373201, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
Study Summary
The aim of this study is to investigate tasimelteon vs. placebo on sleep in healthy individuals after a phase advance in jet lag type insomnia.
Interventions
- DRUG Placebo
- DRUG Tasimelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2018-03-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03373201
The ClinicalTrials.gov registry entry for NCT03373201 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03373201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03373201 about?
NCT03373201 is a clinical study titled "Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia". The aim of this study is to investigate tasimelteon vs. placebo on sleep in healthy individuals after a phase advance in jet lag type insomnia.
What is the current status of trial NCT03373201?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2017-10-16. Estimated completion is 2018-03-05.
What interventions are being tested in trial NCT03373201?
The interventions under investigation include: Placebo (DRUG), Tasimelteon (DRUG).
Who is sponsoring clinical trial NCT03373201?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.